Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity
- 10 July 2026
- journal article
- other
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1289-1291
Abstract
Outcomes following international MDT assessment of adult IEI patients for allogeneic HSCT suggest early referral is vital: patients considered too high risk for transplant have poor outcomes with a 3-year overall survival of 31%.Keywords
This publication has 5 references indexed in Scilit:
- Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert CommitteeJournal of Human Immunity, 2025
- Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunityBlood, 2023
- Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP studyBlood, 2022
- Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiencyBlood, 2018
- Severe combined immunodeficiencies and related disordersNature Reviews Disease Primers, 2015